Brought to you by 
Valeant goes hostile and offers $73/share for Cephalon; withdrawn
Apr 2011
Executive Summary
Taking its offer directly to investors, Valeant Pharmaceuticals International Inc. (focuses on skin and CNS drugs) has publicly announced a $73 per-share cash bid (a 30% premium) for Cephalon Inc., valuing the top-tier biotech at $5.5bn, or almost twice its 2010 sales. Valeant plans to finance the transaction using debt, and wants to replace Cephalon’s board with its own nominees. Beginning earlier this month, Valeant privately approached Cephalon three times, but Valeant says the target did not want to enter into further discussions in a timely manner, and that Cephalon’s CEO believed the board would consider the offer too low.
Deal Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Valeant goes hostile and offers $73/share for Cephalon; withdrawn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice